Daniel A. Guthy

Basel, BS 4056, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D.

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D.

Journal: Journal of medicinal chemistry
Published: July 10, 2025

Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Journal: Nature
Published: July 02, 2025

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.

Journal: Journal of medicinal chemistry
Published: March 31, 2025

Identification and characterization of binders to a cryptic and functional pocket in KRAS.

Identification and characterization of binders to a cryptic and functional pocket in KRAS.

Journal: Nature communications
Published: October 29, 2024

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Journal: Nature
Published: May 08, 2024

Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.

Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.

Journal: Bioconjugate chemistry
Published: January 24, 2024

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.

Journal: Journal of medicinal chemistry
Published: November 18, 2022

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Journal: Journal of medicinal chemistry
Published: May 02, 2022

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Journal: Cancer discovery
Published: February 07, 2022

EndoBind detects endogenous protein-protein interactions in real time.

EndoBind detects endogenous protein-protein interactions in real time.

Journal: Communications biology
Published: January 26, 2021

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Journal: ACS medicinal chemistry letters
Published: October 01, 2019

Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.

Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.

Journal: Cancer chemotherapy and pharmacology
Published: May 16, 2017
Showing 1-12 of 22

Last Updated: 09/26/2026